Lamivudine (generic), Epivir, Epivir-HBV News

Long-term Data Show Telbivudine Suppresses HBV Viral Load and Leads to HBeAg Clearance in Chronic Hepatitis B Patients SUMMARY: At the 60th Annual Meeting of the American Association for the Study of Liver Diseases this month in Boston, researchers reported 4-year data from the GLOBE study, indicating that the nucleoside analog telbivudine ...

SUMMARY: Chronic hepatitis B patients who experience an early decrease in hepatitis B surface antigen starting before week 24 of therapy are more likely to achieve sustained response to pegylated interferon alfa-2a , according to an analysis presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases this month ...

SUMMARY: A systemic review of clinical trials found that pegylated interferon was more effective than the oral antiviral drug lamivudine at achieving endpoints including hepatitis B virus DNA clearance and hepatitis B "e" antigen seroconversion, investigators reported at the 60th Annual Meeting of the American Association for the Study of Liver ...

In a shoe box filled with vitamins and prescription medications, the alledged Fort Hood shooter Major Nidal Malik Hasan had a bottle of the HIV medication Combivir .

BARACLUDE Demonstrated Greater Antiviral Efficacy Compared To Adefovir In New Study Of Chronic Hepatitis B Patients With Cirrhosis Main Category: Liver Disease / Hepatitis Article Date: 03 Nov 2009 - 4:00 PST Bristol-Myers Squibb today announced 48-week data from an ongoing study of chronic hepatitis B patients with decompensated cirrhosis, in ...

Tenofovir Suppresses HBV Viral Load Long-term in HIV/HBV Coinfected Patients, but Kidney Function May Decline SUMMARY: HIV/HBV coinfected individuals treated with agents that are dually active against both virus experience rapid suppression of hepatitis B virus , and about 15% of those taking tenofovir plus emtricitabine achieve hepatitis B "e" ...

Most Patients with Low Baseline HBV Viral Load Can Safely Discontinue Lamivudine after Achieving Virological Suppression Most chronic hepatitis B patients with low pre-treatment HBV DNA levels with pre-treatment HBV DNA < 10 8 copies/mL. This difference in cumulative relapse rates between the 2 groups was statistically significant .

The material posted on HIV and Hepatitis.com about the 49th ICAAC is not approved by the American Society for Microbiology Resistance to Hepatitis B Drugs is Common among HIV-HBV Coinfected Patients Receiving Lamivudine-containing ART without Tenofovir Resistance to the hepatitis B drugs adefovir , entecavir , and telbivudine is common among ...

The most recent issue of Liver Transplantation investigates current management of hepatitis B virus infection before and after liver transplantation.

HIV positive people coinfected with hepatitis B virus respond as well to combination antiretroviral therapy as individuals with HIV alone, but they are more likely to die due to non-AIDS-related causes, according to a study published in the September 10, 2009 issue of AIDS .

About one-quarter of hepatitis B "e" antigen negative patients treated with pegylated interferon alfa-2a for 48 weeks continued to demonstrate sustained biochemical and virological responses up to 3 years after completing therapy, according to a study in the June 2009 issue of Gastroenterology .

A small Kenyan study has contributed new information to the complex body of evidence that is helping researchers identify new strategies for the prevention of mother-to-child transmission of HIV .

Abstract BACKGROUND: Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen and are undergoing chemotherapy.

Abstract BACKGROUND: Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen and are undergoing chemotherapy.

Low baseline HBV viral load was the strongest overall predictor of favorable outcomes for patients treated with telbivudine in the GLOBE trial, with other predictive factors differing between hepatitis B "e" antigen positive and negative participants.

More Treatment News July 30, 2009 by David Evans People taking a regimen including Sustiva appeared to have greater limb fat loss and gut fat accumulation than those on Kaletra -based regimen, according to a study presented at the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town.

The material posted on HIV and Hepatitis.com about IAS 2009 is not approved by nor is it a part of IAS 2009.

More Treatment News July 22, 2009 Pediatric Viramune May Still Work as Treatment in Kids Exposed at Birth by Tim Horn Infants exposed to single-dose Viramune monotherapy at the time of delivery - potentially resulting in rapid resistance to the drug if HIV infection does occur - may still benefit from a Viramune-based treatment regimen, according ...

The material posted on HIV and Hepatitis.com about IAS 2009 is not approved by nor is it a part of IAS 2009.

We thank Dr. Hsu and colleagues for their comments on our meta-analysis. We agree that corticosteroids play an important role in chemotherapy-induced HBV reactivation, which is why we listed corticosteroid use in a dedicated column in Table 1 of our article.